Market withdrawal of new molecular entities approved in the United States from 1980 to 2009

@article{Qureshi2011MarketWO,
  title={Market withdrawal of new molecular entities approved in the United States from 1980 to 2009},
  author={Zaina P. Qureshi and Enrique Seoane-Vazquez and Rosa Rodriguez-Monguio and Kurt Stevenson and Sheryl L. Szeinbach},
  journal={Pharmacoepidemiology and Drug Safety},
  year={2011},
  volume={20}
}
Economic factors, market dynamics, and safety issues are largely responsible for decisions to withdraw pharmaceutical products from the market. In this study, new molecular entities (NMEs) approved by the Food and Drug Administration (FDA) were examined in the USA from 1980 to 2009. 
The withdrawal of drugs for commercial reasons: the incomplete story of tositumomab.
TLDR
Tositumomab was first approved by the US Food and Drug Administration in 2003 for patients with “CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to rituximab and has relapsed following chemotherapy,” according to the prescribing information.
Economics of Fixed-Dose Combination Drugs Approved in the United States
Patents and market exclusivities serve as regulatory incentives to promote pharmaceutical innovation. This study assessed associations between major US regulatory changes enacted in the last three
Evolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and Challenges
TLDR
A workshop was convened to discuss the best practices for the assessment of drug-induced liver injury (DILI) in clinical trials, and the best method to estimate likelihood that a given liver injury was actually caused by the drug in question was discussed.
Approving molecularly targeted drugs: different approval processes for cytotoxic agents
TLDR
Molecularly targeted drugs approved by the PMDA using a flexible process based on drug safety and efficacy should be fully informed about the lack of Japanese data assessment during these approval processes.
DILI and drug development: a regulatory perspective.
  • M. Avigan
  • Medicine
    Seminars in liver disease
  • 2014
TLDR
The development of more effective predictive and analytic tools in preclinical and clinical testing will provide a framework to reliably identify new agents that have hepatotoxic profiles as well as those individuals who are susceptible to develop serious DILI.
Analysis of the Drugs Withdrawn from the US Market from 1976 to 2010 for Safety Reasons
TLDR
The evidence used to justify safety withdrawals is dominated by case reports although there is an increased use of comparative studies.
Critical Aspects of Integrated Nonclinical Drug Development
TLDR
Historical examples are presented from medicines during different phases of drug development highlighting general or specific issues, which, in turn, may have led to modifications of general requirements for the nonclinical characterization of new investigational drugs or to modified of the requirements for risk management and mitigation in humans.
Comparison of Drug Withdrawal Processes in the U.S. and Other Nations
TLDR
This paper explores the drug withdrawal process in several countries due to hepatic and cardiovascular toxicities using the WITHDRAWN database and summarizes and compares the drug removal processes in the U.S., Australia, UK, EU, and Canada.
Novel pre-clinical methodologies for pharmacokinetic drug–drug interaction studies: spotlight on “humanized” animal models
TLDR
Novel pre-clinical animal models, namely, knockout rat/mouse, transgenic rat/Mouse with humanized drug metabolizing enzymes and/or transporters and chimeric rat/ mouse with humanization liver are developed help to validate the in vivo relevance of the in vitro human DDI data.
Approval and Withdrawal of New Antibiotics and other Antiinfectives in the U.S., 1980–2009
TLDR
Professional societies and researchers around the world have called for renewed emphasis on antimicrobial stewardship, while also supporting antibiotic research and development through grants, changes to intellectual property laws to extend market exclusivity periods, and modification of premarket testing regulations to reduce antibiotic development time and expenses.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 24 REFERENCES
Drug withdrawals from the Canadian market for safety reasons, 1963–2004
  • J. Lexchin
  • Medicine
    Canadian Medical Association Journal
  • 2005
By studying drugs that have been withdrawn from the market for safety reasons, we can gain valuable insight into postmarketing surveillance as well as the process for approving new drugs. In the past
The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France
TLDR
The objective of this study was to determine the scientific evidences leading to drug withdrawal for pharmacovigilance reasons in France.
Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates
TLDR
Data on drug approvals and drug-approval times, both as a whole and by therapeutic class, demonstrate that implementation of the PDUFAs led to substantial incremental reductions in approval times beyond what would have been observed in the absence of these legislative acts.
The safety of newly approved medicines: do recent market removals mean there is a problem?
TLDR
The agency's drug review procedures and postmarketing surveillance system after a drug has been marketed are currently adequate but must continually adjust to future challenges.
Canadian and US Drug Approval Times and Safety Considerations
TLDR
Canada avoided potential dangers because its longer approval times provided an opportunity to observe actual market experience in other countries, but the trade-off is that new drugs take significantly longer to be approved in Canada and, hence, to be available to Canadians.
The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals.
TLDR
Case reports are the main source of information used to withdraw a drug from the market for safety reasons and the use of large databases to perform cohort or nested case-control analyses is the most efficient and reliable method to study type-A class effect ADRs.
New active substances authorized in the United Kingdom between 1972 and 1994.
TLDR
There is marked heterogeneity in the annual rates of authorisation of new active substances, and the provisional nature of assessments about safety at the time when a new active substance is introduced into routine clinical practice is confirmed, confirming the importance of pharmacovigilance.
An Assessment of the Publicly Disseminated Evidence of Safety Used in Decisions to Withdraw Medicinal Products from the UK and US Markets
TLDR
It is rare that evidence other than spontaneous reports is cited in support of drug withdrawals, and the serious implications of product withdrawal mandate the elevation of the level of evidence that supports such public health decisions.
Timing of new black box warnings and withdrawals for prescription medications.
TLDR
To determine the frequency and timing of discovery of new ADRs described in black box warnings or necessitating withdrawal of the drug from the market, Examination of the Physicians' Desk Reference for all new chemical entities approved by the US Food and Drug Administration between 1975 and 1999 is examined.
Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends.
TLDR
It is found that a mean of 1.5 drugs per year have been withdrawn since 1993, and that the number of withdrawals has not increased over time, however, some recent drug withdrawals have impacted large numbers of people.
...
1
2
3
...